High prevalence and excess mortality of late presenters among HIV-1, HIV-2 and HIV-1/2 dually infected patients in Guinea-Bissau - a cohort study from West Africa

Bo Langhoff Hønge1,2,3, Sanne Jespersen1,2, Johanna Aunsborg1,2, Delfim Vicente Mendes3, Candida Medina4, David da Silva Té4, Alex Lund Laursen3, Christian Erikstrup3, Christian Wejse1,2,5, The Bissau HIV cohort study group5

1Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau, 2Department of Infectious Diseases, Aarhus University Hospital, Denmark, 3Department of Clinical Immunology, Aarhus University Hospital, Denmark, 4National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau, 5GloHAU, Center for Global Health, School of Public Health, Aarhus University, Denmark

Key words: HIV, late presenters, advanced disease, Guinea-Bissau, HIV-2

Received: 01/11/2015 - Accepted: 06/06/2016 - Published: 29/09/2016

Abstract
Introduction: HIV infected individuals with late presentation (LP) and advanced disease (AD) have been associated with higher mortality, higher cost of medical management, impaired CD4 cell count increment and potentially ongoing risk of HIV transmission. Here we describe the proportion of patients with LP and AD at an HIV clinic in Guinea-Bissau, identify risk factors and evaluate the outcome of these patients. Methods: We included all patients >15 years diagnosed with HIV-1 and/or HIV-2 at the outpatient HIV clinic at Hospital National Simão Mendes, during June 2005 - December 2013 in a retrospective cohort study. Patients were followed until December 2014. LP and AD was defined as a baseline CD4 cell count of 200-349 cells/µL and <200 cells/µL, respectively. Results: A total of 3,720/5,562 (65.7%) patients had a CD4 cell count measured within the first 90 days of HIV diagnosis. Forty-eight percent had AD and 23% had LP. Risk factors for presentation with AD were male sex, age >30 years, Fula and Mandinga ethnicity. HIV-2 and HIV-1/2 dually infected patients had lower risk of AD compared with HIV-1 infected patients. Although antiretroviral therapy (ART) was initiated for 64.4% of patients, those with AD progression had a 3.82 times higher mortality compared to patients with non-LP. Conclusion: The majority of HIV infected patients presented late. Most of the late-presenters had advanced disease and patients with advanced disease had a very high mortality. Initiatives to enroll patients in care at an earlier point are needed and should focus on risk groups.

Pan African Medical Journal. 2016; 25:40 doi:10.11604/pamj.2016.25.40.8329

This article is available online at: http://www.panafrican-med-journal.com/content/article/25/40/full/

© Bo Langhoff Hønge et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

The introduction of antiretroviral treatment (ART) for HIV infection has significantly reduced the morbidity and mortality of HIV infected individuals [1]. However, the success of treatment depends on the disease progression at HIV diagnosis and adequate initiation of ART [2, 3]. Low CD4 cell count at HIV diagnosis termed late presentation (LP) and late presentation with advanced disease (AD) have been associated with higher mortality [4], higher cost of medical management [5], impaired CD4 cell count increment [6, 7] and potentially ongoing risk of HIV transmission [8, 9]. Furthermore, lag time between CD4 cell count measurement and subsequent medical consultation where ART initiation is decided, may contribute to further disease progression and loss to follow-up [10, 11]. Thus, intensified efforts are needed to identify and enroll HIV infected individuals earlier into care [12]. In West Africa, two types of HIV are circulating: HIV-1 and HIV-2. The UNAIDS estimates that in this part of the world less than half of the HIV infected individuals in need of ART are actually receiving the treatment [1]. The West African country Guinea-Bissau has the world’s highest prevalence of HIV-2 and the prevalence of HIV-1 has been rising [13]. Compared with HIV-1, HIV-2 is less transmissible, associated with a lower viral load and with a slower rate of both CD4 cell decline and clinical progression. Still, it may lead to AIDS, with clinical features indistinguishable from the syndrome caused by HIV-1 [14-16]. In this study, we describe the proportion of HIV-1 and/or HIV-2 infected patients with LP and AD at an HIV clinic in Bissau, to identify risk factors thereof and to evaluate the outcome of these patients.

Methods

Setting and patients

In June 2005, the first HIV clinic opened in Bissau, the capital of Guinea-Bissau, providing ART free-of-charge, and the clinic is now the largest ART center in the country in terms of patients on follow-up. CD4 cell count measurements have been performed since 2007, and the same year the Bissau HIV Cohort was established to evaluate patient treatment and follow-up [17]. Routines at the clinic has previously been described [18]. In this retrospective cohort study, patients >15 years were enrolled at the HIV clinic at Hospital National Simão Mendes (HNSM) in Bissau, Guinea-Bissau in the period June 2005 - December 2013. Follow-up continued until December 2014. Active follow-up of absent patients were performed at regular intervals by calling patients or their contact person(s) by telephone. Patients were considered lost to follow-up if on ART and absent for 90 days or without ART and absent for 210 days.

Laboratory methods

CD4 cell counts were performed since April 2007 by flow cytometry using Partec CyFlow® SL_3 (Cyflow SL, Partec, Munster, Germany) at the National Public Health Laboratory. HIV screening was done with a rapid test in the clinic (Determine HIV-1/2 assay, Abbott Laboratories, USA) and confirmation and discrimination using SD Bioline HIV 1/2 3.0 (Standard Diagnostics Inc, Kyonggi-do, South Korea). Since June 2012, the rapid test First Response HIV Card 1-2.0 (PMC Medical, Mumbai, India) has also been used for HIV type discrimination.

Definition of LP and AD

Based on a consensus definition [17] we defined LP as patients presenting for care with a CD4 cell count below 350 cells/µL. AD were defined as patients presenting with a CD4 cell count below 200 cells/µL or presenting with an AIDS-defining event, regardless of the CD4 cell count. Only patients with a CD4 cell count measured within 90 days of HIV diagnosis were included in the analyses.

Statistical methods

We compared the demographic, clinical and laboratory features of patients with AD, LP and non-LP using χ² test for categorical variables. Logistic regression was used for the analysis of risk factors for LP and AD patients when comparing with non-late presenters. In case of missing data, a missing data (unknown) group was made and included in the analysis to avoid exclusion of patients. Variables associated with AD or LP in the univariable model (p<0.10) were included in a multivariable model unless the association was to the group of patients with missing data. Median CD4 cell count and median time to ART were compared between groups using the ANOVA test. Mortality rate ratios (MRR) were calculated using poisson regression analyses. All statistical analyses were carried out using Stata IC 13.0 (StataCorp, College Station, Texas, USA).
Ethical statement

The Bissau HIV cohort has been approved by the national ethics committee in Guinea-Bissau (Parecer NCP/No.15/2007). Upon inclusion, the patients provided a voluntary, signed and dated informed consent, or fingerprint if illiterate.

Results

General characteristics

A total of 5,562 patients were diagnosed with HIV in the study period, but 68 (1.2%) patients were excluded as they were already receiving ART at first CD4 cell count. Furthermore, 1,843 patients (33.1%) were excluded from the analysis as CD4 cell count was not measured within the first 90 days after HIV diagnosis. Excluded patients were more likely to be single versus being married with an odds ratio (OR) of 1.36 (p < 0.01). In addition, a higher proportion of male patients did not have a CD4 cell count measured (OR 1.23, p < 0.01). In the subsequent analysis (Table 1), 3,720 HIV infected patients with a CD4 cell count measurement at diagnosis were included (69.6% HIV-1, 17.9% HIV-2, 10.4% HIV-1/2 and 2.1% HIV type unknown). A total of 2,478 (66.6%) of the patients were of female sex and the median age of all patients were 36 years (interquartile range, IQR 29-45 years).

Description of CD4 cell counts

The median time between HIV diagnosis and initial CD4 cell count measurement was 1 day (IQR 1-5 days). Only a smaller proportion (18.3%) of the patients had CD4 cell count measured the same day as the HIV diagnosis, whereas 33.9% had the analysis performed the following day. Figure 1 presents the CD4 cell count at HIV diagnosis of all patients included. Overall, the median CD4 cell count was 206 cells/µL (IQR 89 - 381). According to our definition, 1,810 (48.7%) patients had AD and 858 (23.1%) had LP; in total 71.8%. The median CD4 cell count at presentation varied during the study period (Figure 2) with the lowest measurements in 2007 (146 cells/µL) and the highest in 2011 (229 cells/µL, p<0.01). There was no significant difference between median CD4 cell count in 2011 and 2013 (199 cells/µL, p=0.33).

Risk factors of LP and AD

Risk factors of AD in the multivariable analysis (Table 2) were male gender (adjusted odds ratio (aOR) 1.49), age 30-49 years (aOR 1.66), age =50 years (aOR 1.48), being single versus married (aOR 1.30), Fula ethnicity (aOR 1.47) and Mandinga ethnicity (aOR 2.04). The proportion of AD among patients with HIV-1 infection was 51.4%, HIV-2 infection 39.3% and HIV-1/2 dual infection 47.4%. Thus, when compared with HIV-1 the aOR of AD for HIV-2 and HIV-1/2 dually infected patients was 0.46 (95% CI 0.37-0.57) and 0.80 (95% CI 0.61-1.05), respectively. Likewise, male gender, age of more than 30 years and single marital status were risk factors of LP. Fewer HIV-2 infected patients (21.7%) than HIV-1 infected patients (23.5%) were late presenters (aOR 0.57, p<0.01).

Initiation of ART

ART was initiated among 2,395 (64.4%) patients during the study period, and this proportion was higher among patients with LP (76.8%) and AD (76.6%) than among patients with non-LP (33.2%), p < 0.001. The overall median time to ART initiation was 18 days (IQR: 9 - 49 days). The median time to ART initiation was lowest for patients with AD (14 days) followed by patients with LP (20 days) and non-LP (266 days, p < 0.001). Only 44 (1.2%) patients initiated ART the same day as they were diagnosed with HIV.

Mortality of patients

All patients were included in the mortality analysis and contributed with 6,950 person-years of observation. During follow-up, 532 deaths were registered; overall mortality rate (MR) = 7.7 (95% CI: 7.03 - 8.33) per 100 person-years. Two-hundred-and-nine (39.3%) of all deaths occurred before initiation of ART (Figure 3). The mortality was most apparent during the first year after HIV diagnosis where 64.3% of the deaths occurred. The mortality rate (MR) was higher among patients with AD (MR 13.1 per 100 person-years (95% CI: 11.9 - 14.4)) than LP (MR 3.8 per 100 person-years (95% CI: 3.0 - 4.8)) and non-LP (MR 2.9 per 100 person-years (95% CI: 2.3 - 3.8)). MRR for AD vs. non-LP was 3.82 (95% CI: 2.9 - 5.0, p < 0.001). There was no significant difference in the mortality between LP and non-LP; MRR 1.31 (95% CI 0.92 - 1.85, p=0.13).
Patients lost to follow-up and patients transferred

According to our definition, 2,169 (58.3%) patients became lost to follow-up during the study period. The proportion of patients lost to follow-up was higher among non-late presenters (67.8%) and patients with LP (60.5%) compared with AD (51.8%, p < 0.001). In total, 178 (4.8%) patients were transferred to another facility with no difference between groups; non-LP (4.5%), LP (5.9%) and AD (4.4%, p=0.19). By the end of the study period 841 (22.6%) of the patients were alive on follow-up.

Discussion

In this cohort, 65.7% of the HIV infected patients had a CD4 cell count measured within the first 90 days of the HIV diagnosis. Almost half the patients presented with AD and additionally one quarter were late presenters. Risk factors of AD were male sex, age > 30 years, marital status single, Fula and Mandinga ethnicity. HIV-2 and HIV-1/2 dually infected patients were less likely to be late presenters. Although ART was initiated for 64.4% of patients, those with AD presentation had an almost four times higher mortality. The Bissau HIV cohort is, to our knowledge, the largest single-center HIV cohort globally in terms of enrolled patients with HIV-2 and HIV-1/2 dual infection. Only few clinical studies on HIV-2 and HIV-1/2 infection have been performed. In sub-Saharan Africa HIV cohorts are characterized by a high rate of loss to follow-up [10, 19] and in a meta-analysis a combined 40% of patient lost to follow-up had in fact died. Thus loss to follow-up in our study may have underestimated the true mortality rate [20]. Another limitation is the uncertainty in the HIV typing. We have previously shown that the rapid test used in Guinea-Bissau for HIV type discrimination (SD Bioline HIV 1/2 3.0) may overestimate the number of HIV-1/2 dually infected patients [21, 22] and the successor (First Response HIV Card Test 1-2.0) has been shown to produce a high number of HIV-positive untypable results. Different definitions of LP have previously been used ranging from a CD4 cell count < 50 cells/µL [23] to CD4 cell count < 200 cells/µL [2]. Other studies have used the term "late diagnosis" as reviewed in a European study [24] and some differentiate between LP and AD whereas others do not [17]. These differences challenge direct comparison between studies. A large study from 132 facilities in Kenya, Mozambique, Rwanda and Tanzania included 334,557 HIV infected adults of whom 19% had AD (CD4 cell count < 100 cells/µL). Risk factors of LP were tuberculosis treatment and a gap of = 12 months gap in pre-ART care [12]. In north-east Ethiopia, 160 cases of patients with CD4 cell count < 200 cells/µL or WHO clinical stage 3-4 (termed late presenters) were compared with 160 controls of patients with CD4 cell count ≥ 200 cells/µL or WHO clinical stage 1-2. The cases more often lived with their families or in a rented house, were non-pregnant women, perceived ART having many side effects, perceived HIV as a stigmatizing disease, tested with sickness/symptoms, did not disclose their HIV status to their partner, frequent alcohol use and had spent more than 120 months with their partner at HIV diagnosis [25]. Among 332 young women in central Mozambique late diagnosis (CD4 cell count < 350 cells/µL) was associated with lack of knowledge of the HIV status of the primary partner and having a gynecological pathology in the last year [26]. In South Africa, 33.6% of 830 patients presented late (CD4 cell count <100 cells/µL), which was associated with living far away from test site, working outside the home, perceiving health service barriers and/or having poor emotional health [27]. A total of 2,311 HIV infected patients were included in a study from Uganda and 40% were late presenters (WHO disease stage 3 or 4). Predictors of late presentation were age 46-60 years (vs. younger), lower educational level, being unemployed, living in a household with others, being unmarried and lack of spousal HIV status disclosure [28]. The numerous risk factors of LP/AD mentioned above indicates the diversity in explanatory causes of late HIV testing and demonstrates the need for local studies. Causes of LP/AD may differ with geographical region and local settings. As in our study, male sex was a risk factor of LP in many of these African studies possibly reflecting a poorer health-seeking behavior in the male population [12, 26-29]. In Bissau male sex is also associated with higher rates of loss to follow-up after CD4 cell count measurement [10].

Implications

Among all patients diagnosed with HIV at our clinic, 33.1% did not have a CD4 cell count measured within 90 days of HIV diagnosis and were excluded from further analysis. Due to unstable supply of reagents for flow cytometry and because of machine breakdowns, CD4 cell counts were not available for patients several times during the study period. Furthermore, Guinea-Bissau has been considered politically unstable for many years and coup attempts have closed down HIV clinic whereas the laboratory have been closed down occasionally because of work-force strikes when salaries were not paid [30]. These mere practical issues may explain why excluded
patients did not differ much from the patients with a CD4 cell count measured. Only 18.3% of the patients in this study had a CD4 cell count performed on the same day as the HIV diagnosis and 1.2% initiated ART on the day of the HIV diagnosis. In Bissau, the CD4 cell counts were measured at a central laboratory across town which meant, that the result would usually not be available for clinicians until at least the day after and physicians may have been reluctant to initiate ART before knowing the CD4 cell count of the patient. This would have caused delayed ART initiation with a risk of the patients not showing up at the clinic again; a missed opportunity. Point-of-care CD4 testing has been evaluated in a recent review analysis including 15 studies mainly from sub-Saharan Africa. When comparing with conventional laboratory-based testing, the point-of-care CD4 testing increased the likelihood of having a CD4 cell count measured and having received the CD4 result. Overall, time between HIV diagnosis and CD4 measurement was reduced by 9 days [31]. However, the performance of different point-of-care devices for CD4 cell count varies with regard to accuracy and costs [32]. The implementation of point-of-care monitoring tools at decentralized clinic laboratories may therefore be warranted [33]. HIV-2 infected patients presented with higher CD4 cell counts in our study. Individuals with HIV-2 infection often have slower disease progression compared with those with HIV-1 infection [14, 15]. A proportion of the patients enrolled under care at the HIV clinic at HNSM are tested for HIV infection as part of routine screenings procedures (pregnant women, students, blood donors) explaining their referral to the HIV clinic and early presentation. Controversially, studies have suggested that initial infection with HIV-2 may protect against subsequent HIV-1 disease progression [34, 35] whereas other studies did not find a protective effect [36]. Based on the HIV tests used, we found that HIV-1/2 dually infected patients were significantly less likely to have AD than HIV-1 infected patients. A recent meta-analysis of 56 studies from Sub-Saharan Africa found that the overall median CD4 cell count in 2002 was 251 cells/µL [37]. The median CD4 count was somewhat lower in our study (206 cells/µL). Due to intermittently unavailable CD4 cell count measurements and low stock or no HIV tests in Bissau, physicians may have prioritized blood analyses for the clinically sickest patients. The aforementioned meta-analysis also found that the CD4 cell count did not change between 2002 - 2013, except for patients living in South Africa. We observed an increase in CD4 cell count at presentation from 2007 to 2011. CD4 cell count measurements and large scale ART did not become available in Guinea-Bissau until 2007, and the first patients enrolled in care were likely those in greatest needs of care. The relatively late introduction of ART in Guinea-Bissau may also explain why age >30 years was a risk factor of AD in our study period. On average, time since infection may be longer for older patients causing more severe disease progression. Low self-perceived risk of HIV infection among older patients may also explain later presentation [28]. Cultural differences between different ethnicities may influence time of presentation at an HIV clinic. Fula and Mandinga ethnicity, which were associated with AD in this study, constitutes two major population group in West Africa. In Guinea-Bissau distinct living conditions and cultural patterns are practiced in these ethnic groups, participation in vaccination campaigns are lower and child mortality is higher than in other groups [38-41]. Similarly, the mortality rate was higher in these ethnic groups among women of reproductive age [42]. HIV-1 infection was also associated with Mandinga ethnicity in a study among pregnant women in Bissau [43]. Association between AD and Fula/Mandinga ethnicity may reflect differences in geographic origin [42], socioeconomic characteristics and health seeking behavior [40]. During the study period, the WHO recommendations for initiation of ART based on CD4 cell count changed. Previously only patients with CD4 cell count below 200 cells/µL were recommended to initiate ART, but in 2010 the recommendations changed to 350 cells/µL or less. The national guidelines in Guinea-Bissau have followed these recommendations from WHO [44], although the newest guidelines suggesting ART initiation at a CD4 cell count below 500 cells/µL had not yet been implemented at the end of the study period. ART is provided free-of-charge for patients, but still, approximately 25% of patients with AD in our study did not initiate ART. Early mortality was very high for patients with AD, but may be improved with rapid initiation of ART. We have previously described that loss to follow-up bears a significant cause of the failure to start ART both before and after the first CD4 cell count [10].

Unanswered questions for future research

As patients with AD have higher mortality rates, it should be of high priority to investigate the causes of LP/AD at HIV testing. Additional HIV screening of the population among high-risk groups may induce infected individuals to be enrolled under care at an earlier point.
Conclusion

A high proportion of HIV infected patients had AD and these patients exhibited a much higher mortality. Initiatives to enroll patients in care at an earlier point are needed and should focus on risk groups.

What is known about this topic
- Late presentation of HIV infected patients causes delayed initiation of antiretroviral therapy;
- In other settings, late presentation has been associated with higher mortality and impaired CD4 cell count increment;
- Little is known about the extent and significance of late presentation in Guinea-Bissau.

What this study adds
- More than half of the HIV infected patients in Bissau were late presenters;
- HIV-1 infected patients presented with lower CD4 cell count than HIV-2 infected patients;
- Despite antiretroviral therapy, late presenters with advanced disease progression had an almost 4 times higher mortality rate.

Competing interests

The authors declare no competing interest.

Authors’ contributions

BLH, SJ, JA, ALL, CE and CW conceived the study; BLH, CM and DdaS carried out clinical assessment; BLH, SJ, JA, DVM, ALL, CE, and CW carried out analysis and interpretation of data. BLH, SJ and CW drafted the manuscript; SJ, JA, DVM, ALL, CW and CE critically revised the manuscript for intellectual content. All authors read and approved the final manuscript. BLH and CW are guarantors of the paper.

Acknowledgments

The authors are grateful to the clinic assistants Aminata, Quintino, Marques, João Paulo, Imbemba, Zé and the rest of the staff working in the HIV clinic at HNSM for their dedication to work and kindness with patients. We are also grateful to the laboratory staff working at the HIV section at the National Public Health Laboratory and to the office staff at the Bandim Health Project for making this study possible. The Bissau HIV cohort study group comprises Amabelia Rodrigues, David da Silva, Zacarias da Silva, Candida Medina, Ines Oliveira-Souto, Lars Ostergaard, Alex Laursen, Sanne Jespersen, Peter Aaby, Anders Fomsgaard, Christian Erikstrup, Bo Langhoff Hønge and Christian Wejse (chair).

Tables and figures

Table 1: Characteristics of all included patients
Table 2: Risk factors of late presenters with advanced disease (AD) versus non-late presenters (non-LP)
Figure 1: Number of patients by CD4 cell count at HIV diagnosis
Figure 2: CD4 cell count by year of HIV diagnosis
Figure 3: Patient mortality by time from HIV diagnosis

References

1. WHO Report. Global update on HIV treatment 2013: Results, Impact and Opportunities. http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2013/20130630_treatment_report_en.pdf (accessed 3 Apr 2015). Google Scholar

2. Mocroft A, Lundgren JD, Sabin ML et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med. 2013; 10(9): e1001510. PubMed | Google Scholar

3. Helleberg M, Engsig FN, Kronborg G et al. Late presenters, repeated testing, and missed opportunities in a Danish nationwide HIV cohort. Scand J Infect Dis. 2012; 44(4): 282-8. PubMed | Google Scholar
4. Antinori A, Coenen T, Costagiola D et al. Late presentation of HIV infection: a consensus definition. HIV Med. 2011; 12(1): 61-4. PubMed | Google Scholar

5. Lawn SD, Harries AD, Anglaret X et al. Early mortality among adults accessing antiretroviral treatment programs in sub-Saharan Africa. AIDS Lond Engl. 2008; 22(15): 1897-908. PubMed | Google Scholar

6. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 < 200 cells/microL) with HIV infection. HIV Med. 2004; 5(2): 93-8. PubMed | Google Scholar

7. Nash D, Katyal M, Brinkhof MWG et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS Lond Engl. 2008; 22(17): 2291-302. PubMed | Google Scholar

8. Robbins GK, Spritzler JG, Chan ES et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009; 48(3): 350-61. PubMed | Google Scholar

9. Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6): 493-505. PubMed | Google Scholar

10. Marks G, Crepaz N, Senterfitt JW et al. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 1999. 2005; 39(4): 446-53. PubMed | Google Scholar

11. Honge BL, Jespersen S, Nordentoft PB et al. Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. BMJ Open. 2013; 3(10): e003499. PubMed | Google Scholar

12. Marcellin F, Abé C, Loubière S et al. Delayed first consultation after diagnosis of HIV infection in Cameroon. AIDS Lond Engl. 2009; 23(8): 1015-9. PubMed | Google Scholar

13. Lahuerta M, Wu Y, Hoffman S et al. Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014; 58(3): 432-41. PubMed | Google Scholar

14. Da Silva ZJ, Oliveira I, Andersen A et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS Lond Engl. 2008; 22(10): 1195-202. PubMed | Google Scholar

15. Rowland-Jones SL, Whittle HC. Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1? Nat Immunol. 2007; 8(4): 329-31. PubMed | Google Scholar

16. Campbell-Yesufu OT, Gandhi RT. Update on Human Immunodeficiency Virus (HIV)-2 Infection. Clin Infect Dis. 2011; 52(6): 780-7. PubMed | Google Scholar

17. Oliveira I, Andersen A, Furtado A et al. Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. BMJ Open. 2012; 2(6): e001587. PubMed | Google Scholar

18. Jespersen S, Honge BL, Oliveira I et al. Cohort Profile: The Bissau HIV Cohort—a cohort of HIV-1, HIV-2 and co-infected patients. Int J Epidemiol. 2015 Jun; 44(3): 756-63. PubMed | Google Scholar

19. Mugglin C, Estill J, Wandeler G et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health TM IH. 2012; 17(12): 1509-20. PubMed | Google Scholar

20. Brinkhof MWG, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PloS One. 2009; 4(6): e5790. PubMed | Google Scholar
21. Hønge BL, Bjarnason Obinah MP, Jespersen S et al. Performance of 3 rapid tests for discrimination between HIV-1 and HIV-2 in Guinea-Bissau, West Africa. J Acquir Immune Defic Syndr 1999. 2014; 65(1): 87-90. PubMed | Google Scholar

22. Hønge BL, Jespersen S, Pétur Bjarnason MO et al. Inter-observer variation of the rapid test SD Bioline HIV 1/2 3 0 for HIV type discrimination: experiences from Guinea-Bissau. J Acquir Immune Defic Syndr. 2015 Feb 1; 68(2): e23-5. PubMed | Google Scholar

23. Sabin CA, Smith CJ, Gumley H et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS Lond Engl. 2004; 18(16): 2145-51. PubMed | Google Scholar

24. Adler A, Mounier-Jack S, Coker RJ. Late diagnosis of HIV in Europe: definitional and public health challenges. AIDS Care. 2009; 21(3): 284-93. PubMed | Google Scholar

25. Abaynew Y, Deribew A, Deribe K. Factors associated with late presentation to HIV/AIDS care in South Wollo ZoneEthiopia: a case-control study. AIDS Res Ther. 2011 Feb 28; 8: PubMed | Google Scholar

26. Zango A, Dubé K, Kelbert S et al. Determinants of prevalent HIV infection and late HIV diagnosis among young women with two or more sexual partners in Beira, Mozambique. PloS One. 2013; 8(5): e63427. PubMed | Google Scholar

27. Drain PK, Losina E, Parker G et al. Risk factors for late-stage HIV disease presentation at initial HIV diagnosis in Durban, South Africa. PloS One. 2013; 8(1): e55305. PubMed | Google Scholar

28. Kigozi IM, Dobkin LM, Martin JN et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr. 2009 Oct 1; 52(2): 280-9. PubMed | Google Scholar

29. Jespersen S, Hønge BL, Esbjörnsson J et al. Differential effects of sex in a West African cohort of HIV-1, HIV-2 and HIV-1/2 dually infected patients: men are worse off. Trop Med Int Health. 2016; 21(2): 253-62. PubMed | Google Scholar

30. Jespersen S, Hønge BL, Oliveira I et al. Challenges facing HIV treatment in Guinea-Bissau: the benefits of international research collaborations. Bull World Health Organ. 2014; 92(12): 909-14. PubMed | Google Scholar

31. Wynberg E, Cooke G, Shroufi A et al. Impact of point-of-care CD4 testing on linkage to HIV care: a systematic review. J Int AIDS Soc. 2014 Jan 20; 17: 18809. PubMed | Google Scholar

32. Rowley CF. Developments in CD4 and viral load monitoring in resource-limited settings. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014; 58(3): 407-12. PubMed | Google Scholar

33. Chaillet P, Tayler-Smith K, Zachariah R et al. Evaluation of four rapid tests for diagnosis and differentiation of HIV-1 and HIV-2 infections in Guinea-Conakry, West Africa. Trans R Soc Trop Med Hyg. 2010; 104(9): 571-6. PubMed | Google Scholar

34. Esbjörnsson J, Månsson F, Kvist A et al. Inhibition of HIV-1 Disease Progression by Contemporaneous HIV-2 Infection. N Engl J Med. 2012; 367(3): 224-32. PubMed | Google Scholar

35. Esbjörnsson J, Månsson F, Kvist A et al. Effect of HIV-2 infection on HIV-1 disease progression and mortality. AIDS Lond Engl. 2014; 28(4): 614-5. PubMed | Google Scholar

36. Prince PD, Matser A, van Tienen C et al. Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis. AIDS Lond Engl. 2014; 28(4): 549-58. PubMed | Google Scholar

37. Siedner MJ, Ng CK, Bassett IV et al. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015; 60(7): 1120-7. PubMed | Google Scholar

38. Aaby P, Bukh J, Lisse IM et al. Spacing, crowding, and child mortality in Guinea-Bissau. Lancet. 1983; 2(8342): 161. PubMed | Google Scholar
39. Fisker AB, Aaby P, Bale C et al. Does the effect of vitamin A supplements depend on vaccination status? An observational study from Guinea-Bissau. BMJ Open. 2012; 2(1): e000448. PubMed | Google Scholar

40. Fazzio I, Mann V, Boone P. Temporal trends (1977-2007) and ethnic inequity in child mortality in rural villages of southern Guinea Bissau. BMC Public Health. 2011 Sep 2; 11: 683. PubMed | Google Scholar

41. Quattrochi J, Jasseh M, Mackenzie G et al. Spatial analysis of under-5 mortality and potential risk factors in the Basse Health and Demographic Surveillance System, the Gambia. Trop Med Int Health. 2015 Jul; 20(7): 941-51. PubMed | Google Scholar

42. Mane M, Fisker AB, Ravn H et al. Trends and determinants of mortality in women of reproductive age in rural Guinea-Bissau, West Africa--a cohort study. BMC Womens Health. 2013 Dec 5; 13: 48. PubMed | Google Scholar

43. Gianelli E, Riva A, Rankin Bravo FA et al. Prevalence and risk determinants of HIV-1 and HIV-2 infections in pregnant women in Bissau. J Infect. 2010; 61(5): 391-8. PubMed | Google Scholar

44. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1 (accessed 3 Apr 2015). Google Scholar
| Table 1: Characteristics of all included patients |
|-----------------------------------------------|
| Advanced disease (AD) | Late presentation (LP) | Non-late presentation (non-LP) | p-value |
|-----------------------|------------------------|-------------------------------|---------|
| n (%)                 | n (%)                  | n (%)                         |         |
| In total              |                        |                               |         |
| 1810                  | 858                    | 1051                          |         |
| **HIV-type**          |                        |                               | <0.01   |
| HIV-1                 |                        |                               |         |
| 1329 (73.4)           | 608 (70.9)             | 650 (61.8)                    |         |
| HIV-2                 |                        |                               |         |
| 262 (14.5)            | 144 (16.8)             | 260 (24.7)                    |         |
| HIV-1/2               |                        |                               |         |
| 185 (10.2)            | 94 (11.0)              | 110 (10.5)                    |         |
| Unknown               |                        |                               |         |
| 34 (1.9)              | 12 (1.4)               | 31 (3.0)                      |         |
| **Sex**               |                        |                               | <0.01   |
| Female                |                        |                               |         |
| 1134 (62.7)           | 571 (66.6)             | 773 (73.5)                    |         |
| Male                  |                        |                               |         |
| 676 (37.3)            | 287 (33.4)             | 278 (26.5)                    |         |
| **Age stratified**    |                        |                               | <0.01   |
| Age ≤ 30 years        |                        |                               |         |
| 466 (25.8)            | 246 (28.7)             | 339 (32.2)                    |         |
| Age 30-49 years       |                        |                               |         |
| 1112 (61.4)           | 491 (57.2)             | 557 (53.0)                    |         |
| Age ≥ 50 years        |                        |                               |         |
| 221 (12.2)            | 117 (13.6)             | 152 (14.5)                    |         |
| Unknown               |                        |                               |         |
| 11 (0.6)              | 4 (0.5)                | 3 (0.3)                       |         |
| **Marital status**    |                        |                               | <0.01   |
| Married               |                        |                               |         |
| 1014 (56.0)           | 443 (51.6)             | 576 (54.8)                    |         |
| Divorced              |                        |                               |         |
| 118 (6.5)             | 36 (4.2)               | 67 (6.4)                      |         |
| Widowed               |                        |                               |         |
| 235 (13.0)            | 131 (15.3)             | 169 (16.1)                    |         |
| Single                |                        |                               |         |
| 414 (22.9)            | 236 (27.5)             | 221 (21.0)                    |         |
| Unknown               |                        |                               |         |
| 29 (1.6)              | 12 (1.4)               | 18 (1.7)                      |         |
| **Ethnicity**         |                        |                               | <0.01   |
| Balanta               |                        |                               |         |
| 268 (14.8)            | 168 (19.6)             | 209 (19.9)                    |         |
| Fula                  |                        |                               |         |
| 363 (20.1)            | 152 (17.7)             | 192 (18.3)                    |         |
| Mandinga              |                        |                               |         |
| 189 (10.4)            | 78 (9.1)               | 72 (6.9)                      |         |
| Manjaco               |                        |                               |         |
| 130 (7.2)             | 67 (7.8)               | 84 (8.0)                      |         |
| Pepel                 |                        |                               |         |
| 140 (7.7)             | 60 (7.0)               | 84 (8.0)                      |         |
| Mancanha              |                        |                               |         |
| 95 (5.3)              | 68 (7.9)               | 70 (6.7)                      |         |
| Other*                |                        |                               |         |
| 279 (15.4)            | 153 (17.8)             | 168 (16.0)                    |         |
| Unknown               |                        |                               |         |
| 346 (19.1)            | 112 (13.1)             | 172 (16.4)                    |         |
| **Attended school**   |                        |                               | 0.42    |
| Yes                   |                        |                               |         |
| 1129 (62.4)           | 546 (53.4)             | 650 (61.9)                    |         |
| No                    |                        |                               |         |
| 609 (33.7)            | 287 (33.5)             | 370 (35.2)                    |         |
| Unknown               |                        |                               |         |
| 72 (4.0)              | 25 (2.9)               | 31 (2.9)                      |         |
| **Year of diagnosis** |                        |                               | 0.01    |
| 2007                  |                        |                               |         |
| 126 (7.0)             | 42 (4.9)               | 46 (4.4)                      |         |
| 2008                  |                        |                               |         |
| 272 (15.0)            | 120 (14.0)             | 128 (12.2)                    |         |
| 2009                  |                        |                               |         |
| 348 (19.2)            | 151 (17.6)             | 186 (17.7)                    |         |
| 2010                  |                        |                               |         |
| 366 (20.2)            | 201 (23.4)             | 238 (22.7)                    |         |
| 2011                  |                        |                               |         |
| 283 (15.6)            | 162 (18.9)             | 207 (19.7)                    |         |
| 2012                  |                        |                               |         |
| 224 (12.4)            | 102 (11.9)             | 136 (12.9)                    |         |
| 2013                  |                        |                               |         |
| 191 (10.6)            | 80 (9.3)               | 110 (10.5)                    |         |

*Other ethnicities: Beafada, Bijago, Caboverdeano, Felupe, Mansconca and mixed

**Not including koranic school
Table 2: Risk factors of late presenters with advanced disease (AD) versus non-late presenters (non-LP)

|                      | Advanced disease (AD) <200 cells/µL |                      | Multivariable analysis |                      |
|----------------------|-------------------------------------|----------------------|------------------------|----------------------|
|                      | Univariable analysis                | Multivariable analysis |                        |                      |
|                      | OR (95% CI)                         | P-value              | OR (95% CI)            | P-value              |
| HIV-type             |                                     |                      |                        |                      |
| HIV-1                | 1.00                                | -                    | 1.00                   | -                    |
| HIV-2                | 0.49 (0.40-0.60)                    | <0.01                | 0.46 (0.37-0.57)       | <0.01                |
| HIV-1/2              | 0.82 (0.63-1.05)                    | 0.12                 | 0.80 (0.61-1.05)       | 0.11                 |
| Sex                  |                                     |                      |                        |                      |
| Female               | 1.00                                | -                    | 1.00                   | -                    |
| Male                 | 1.66 (1.41-1.96)                    | <0.01                | 1.49 (1.24-1.80)       | <0.01                |
| Age stratified       |                                     |                      |                        |                      |
| Age ≤ 30 years       | 1.00                                | -                    | 1.00                   | -                    |
| Age 30-49 years      | 1.52 (1.27-1.81)                    | <0.01                | 1.66 (1.36-2.02)       | <0.01                |
| Age ≥ 50 years       | 1.10 (0.85-1.42)                    | 0.45                 | 1.48 (1.10-1.99)       | 0.01                 |
| Marital status       |                                     |                      |                        |                      |
| Married              | 1.00                                | -                    | 1.00                   | -                    |
| Divorced             | 0.99 (0.72-1.36)                    | 0.96                 | 1.03 (0.74-1.44)       | 0.86                 |
| Widowed              | 0.79 (0.63-0.99)                    | 0.04                 | 1.00 (0.78-1.28)       | 0.98                 |
| Single               | 1.06 (0.88-1.29)                    | 0.53                 | 1.30 (1.05-1.61)       | <0.01                |
| Ethnicity            |                                     |                      |                        |                      |
| Balanta              | 1.00                                | -                    | 1.00                   | -                    |
| Fula                 | 1.47 (1.14-1.89)                    | <0.01                | 1.55 (1.19-2.02)       | <0.01                |
| Mancanha             | 1.05 (0.74-1.51)                    | 0.77                 | 1.15 (0.79-1.68)       | 0.45                 |
| Mandinga             | 2.04 (1.47-2.83)                    | <0.01                | 2.10 (1.50-2.95)       | <0.01                |
| Manjaco              | 1.20 (0.87-1.67)                    | 0.27                 | 1.22 (0.87-1.72)       | 0.25                 |
| Pepel                | 1.29 (0.94-1.79)                    | 0.12                 | 1.28 (0.91-1.81)       | 0.16                 |
| Other*               | 1.29 (0.99-1.68)                    | 0.06                 | 1.35 (1.03-1.78)       | 0.03                 |
| Attended school**    |                                     |                      |                        |                      |
| Yes                  | 1.00                                | -                    | -                      | -                    |
| No                   | 0.94 (0.80-1.11)                    | 0.47                 | -                      | -                    |
| Year of diagnosis    |                                     |                      |                        |                      |
| 2007                 | 1.00                                | -                    | 1.00                   | -                    |
| 2008                 | 0.78 (0.52-1.15)                    | 0.21                 | 0.71 (0.47-1.09)       | 0.12                 |
| 2009                 | 0.68 (0.47-1.00)                    | 0.05                 | 0.64 (0.43-0.96)       | 0.03                 |
| 2010                 | 0.56 (0.39-0.82)                    | <0.01                | 0.51 (0.34-0.75)       | <0.01                |
| 2011                 | 0.50 (0.34-0.73)                    | <0.01                | 0.45 (0.30-0.68)       | <0.01                |
| 2012                 | 0.60 (0.40-0.90)                    | 0.01                 | 0.52 (0.34-0.79)       | <0.01                |
| 2013                 | 0.63 (0.42-0.95)                    | 0.03                 | 0.50 (0.33-0.78)       | <0.01                |

*Other ethnicities: Beafada, Bijago, Caboverdeano, Felupe, Mansonca and mixed

**Not including koranic school
Figure 1: Number of patients by CD4 cell count at HIV diagnosis

Figure 2: CD4 cell count by year of HIV diagnosis
Figure 3: Patient mortality by time from HIV diagnosis

| CD4 Level  | Time (years) | Number at Risk |
|-----------|--------------|----------------|
| CD4 <200  | 0            | 1811           |
|           | 1            | 880            |
|           | 2            | 603            |
|           | 3            | 407            |
|           | 4            | 259            |
|           | 5            | 144            |
|           | 6            | 65             |
|           | 7            | 28             |
| CD4 200-349 | 0       | 1051           |
|           | 1            | 627            |
|           | 2            | 417            |
|           | 3            | 250            |
|           | 4            | 160            |
|           | 5            | 91             |
|           | 6            | 37             |
|           | 7            | 9              |
| CD4 >350  | 0            | 858            |
|           | 1            | 503            |
|           | 2            | 359            |
|           | 3            | 236            |
|           | 4            | 141            |
|           | 5            | 78             |
|           | 6            | 35             |
|           | 7            | 11             |